Molecular Partners AG
Molecular Partners AG (MOLN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MOLN · as of Jun 9, 2026
Key Statistics
Explore Molecular Partners AG Data
moln stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 25.0%
The MOLN analyst consensus is Hold, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $13.00, representing +229.11% upside from the current price of $3.95.
Competitors & Peers
moln competitorsMOLN
ALEC
APLT
CRBP
CRDF
ELTXStock Performance
Full HistoryAbout Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipe…
what is molecular partners ag · moln stock overview · molecular partners ag company profile · who is molecular partners ag ceo · moln NASDAQ · molecular partners ag headquarters · molecular partners ag business segments
About Stock Overview & Key Data
Molecular Partners AG (MOLN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 16, 2021. As of the latest trading session, MOLN stock price is $3.95, with a market capitalization of $148.2M. The stock has returned +1.54% over the past 12 months and -9.40% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Molecular Partners AG stock is Hold, with an average 12-month price target of $13.00. In fiscal year 2025, Molecular Partners AG reported revenue of — and net income of -$61.7M. For detailed data — including Molecular Partners AG revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Molecular Partners AG (MOLN) stock price is $3.95. The stock is traded on NASDAQ under the ticker symbol MOLN. The 52-week range is $3.41 – $5.36.